Skip to main content
$46.84 -$1.04 (-2.2%)

04:00 PM EST on 01/21/21

Bluebird Bio Inc. (NASDAQ:BLUE)

CAPS Rating: 5 out of 5

Current Price $46.84 Mkt Cap $3.2B
Open $47.90 P/E Ratio 0.00
Prev. Close $47.88 Div. (Yield) $0.00 (0.0%)
Daily Range $46.77 - $48.11 Volume 953,135
52-Wk Range $38.95 - $96.63 Avg. Daily Vol. 1,152,489

Caps

How do you think NASDAQ:BLUE will perform against the market?

Add Stock to CAPS Watchlist

All Players

253 Outperform
15 Underperform
 

All-Star Players

122 Outperform
4 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:BLUE Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

mdriver78 (76.29)
Submitted May 07, 2020

A company making big strides in gene therapies for genetic diseases and cancer. As a "clinical-stage company," Bluebird performs a lot of the early research to see what does and doesn’t work on certain diseases. Any treatments that Bluebird then… More

TMFacarchidi (59.69)
Submitted July 16, 2020

Extended delays with getting regulatory approval in the U.S., IP infringement lawsuits against them, and competing in several very crowded disease therapeutics markets where it has no clear product advantage over the competition.

NASDAQ:BLUE VS S&P 500 (SPY)

Fools bullish on NASDAQ:BLUE are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about BLUE.

Recs

0
Member Avatar italianbarber (96.13) Submitted: 6/4/2020 2:30:46 PM : Outperform Start Price: $67.82 NASDAQ:BLUE Score: -54.51

Lots of things in the pipeline and the stock has gotten killed.

Recs

0
Member Avatar jimbo19 (92.61) Submitted: 5/13/2020 5:56:18 PM : Outperform Start Price: $57.21 NASDAQ:BLUE Score: -55.88

If their developments get to the customer, this will be a rocket ship. Otherwise I’ll have egg on my face.

Recs

2
Member Avatar mdriver78 (76.29) Submitted: 5/7/2020 10:23:09 AM : Outperform Start Price: $55.09 NASDAQ:BLUE Score: -50.16

A company making big strides in gene therapies for genetic diseases and cancer.

As a "clinical-stage company," Bluebird performs a lot of the early research to see what does and doesn’t work on certain diseases. Any treatments that Bluebird then develops can be sold or licensed to larger drug companies for mass production.

The biotech is particularly known for its cancer treatment "bb2121," which is partly licensed by Bristol-Myers (BMY).

BLUE also has a pipeline of other potential therapies that could eventually be great for BMY if and when they are approved by the FDA.

And I think this pipeline of potential treatments is the reason for the mysterious trades that our One Day Bonus Indicator picked up on.
You see, if BLUE develops a working therapy for a disease that affects a large group of people worldwide, it could be worth tens of billions of dollars to a giant drug company like BMY.

And since BMY and BLUE already have a licensing arrangement, it’s easy to imagine that BMY will hear rumors of any of BLUE’s successes before the news goes public.

That brings into focus a series of options trades of late.

Those transactions include a major buy of January $200 call contracts on BLUE and January $240 call contracts.
The thing is, BLUE shares currently trade for around $55. So the $240 calls will only pay off if BLUE’s price jumps 320%!

Could certainly speculate that the only reason a trader in his right mind would make this type of speculative trade is if he had some sort of high-conviction information about what’s happening behind the scenes at BLUE. It just wouldn't make sense otherwise.

It may be a chance to score big on a buyout of this small biotech development company.

Initiate a buyout play before a big drug company swoops in and makes a major buyout announcement!

The company already has a license agreement with BMY, and could be a juicy target for BMY to take over entirely.

But even if a deal doesn’t materialize, we can still do quite well with this trade. BLUE has a number of promising therapies in the pipeline and could quickly monetize any approved drug by licensing to a major distributor.

Leaderboard

Find the members with the highest scoring picks in BLUE.

Score Leader

DoubleBagel

DoubleBagel (35.12) Score: +669.10

The Score Leader is the player with the highest score across all their picks in BLUE.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. CommodityBuyer < 20 7/10/2015 Underperform 5Y $160.69 -70.85% +85.27% +156.12 0 Comment
MotleyFolJohn < 20 2/2/2015 Underperform 1Y $93.98 -50.16% +92.43% +142.59 1 Comment
GreenAB 28.27 3/5/2015 Underperform NS $106.20 -55.89% +82.32% +138.22 0 Comment
pro64grammer 28.63 12/9/2014 Underperform 5Y $79.58 -41.14% +87.72% +128.86 0 Comment
coptermech66 < 20 10/29/2015 Underperform 3Y $79.54 -41.11% +84.01% +125.13 1 Comment
baselineace 22.80 11/13/2017 9/6/2020 Underperform 5Y $151.50 -69.08% +49.33% +118.41 0 Comment
biotechf 91.30 1/22/2016 Underperform 3M $44.44 +5.40% +102.96% +97.56 0 Comment
3rdChanceTom 90.73 3/11/2016 Underperform 5Y $45.77 +2.34% +90.92% +88.58 0 Comment
genedom 90.03 8/31/2016 Underperform 3Y $49.10 -4.60% +76.69% +81.29 1 Comment
secohen11 23.64 7/2/2013 Underperform 1Y $26.20 +78.78% +138.48% +59.70 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for BLUE.